NEWS Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Decatur, IL 7 October 2025 LEARN MORE
NEWS Life Molecular Imaging Expands Neuraceq® (florbetaben F-18 injection) Production in Southern California 19 August 2025 LEARN MORE
NEWS Life Molecular Imaging Announce Successful First Production of NeuraCeq® (Florbetaben [18F]) in Solna, Sweden 9 July 2025 LEARN MORE
NEWS FDA Expands Indications for Neuraceq®, an Amyloid PET Imaging Agent, to Enhance Diagnosis and Care of Patients with Alzheimer’s Disease 30 June 2025 LEARN MORE
NEWS Life Molecular Imaging announces presentation of new scientific data at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2025 20 June 2025 LEARN MORE
NEWS European Commission Grants Orphan Drug Designation to Florbetaben (18F) for Diagnosis of ATTR Amyloidosis 12 June 2025 LEARN MORE
NEWS Life Molecular Imaging and SOFIE announce Neuraceq® availability in Albany, NY 20 May 2025 LEARN MORE
NEWS Life Molecular Imaging Secures Funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to Further Investigate [18F]F-DED PET in Alzheimer’s Neuroinflammation 14 May 2025 LEARN MORE
NEWS Life Molecular Imaging announces Neuraceq® availability at PharmaLogic Salt Lake City 24 April 2025 LEARN MORE
NEWS Florbetaben (18F) Injection (Neuraceq®) Set to Launch at St. Teresa’s Hospital in Hong Kong in March 2025 14 March 2025 LEARN MORE
